Grant: Doctoral: Vanier Canada Graduate Scholarships
Université de Montréal
$150,000.00
Inhibiting Interleukin-1 receptor during pregnancy to prevent neonatal mortality and morbidity induced by placental/chorioamniotic inflammation
EF 2015-16
Résumé
Inflammation inside the uterus is responsible for most of pregnancy complications, including preterm birth. Preterm birth is the leading cause of neonatal mortality and morbidity, and is associated with many diseases of the newborn which subject the infant to long-term disabilities. Of all inflammation mediators, interleukin-1 has been identified as a key player in uterine inflammation. However, currently available therapies that target interleukin-1 have failed to show expected efficacy at decreasing inflammation in gestational tissue. Our laboratory has recently developed a promising agent (termed 101.10) that targets interleukin-1 and decreases gestational inflammation. Preliminary data shows that it is also effective at improving newborn's health and decreasing long-term developmental problems. The proposed project aims to evaluate 101.10 efficacy, when administrated during gestation threatened by inflammation, to improve neonatal outcomes.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
339562
Name
Nadeau-Vallée Mathieu
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Inhibiting Interleukin-1 receptor during pregnancy to prevent neonatal mortality and morbidity induced by placental/chorioamniotic inflammation
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Allosteric Modulator; Chorioamnionitis; Fetal Brain; Immunity; Inflammation; Interleukin-1; Neonatal Morbidity; Pregnancy Outcomes; Preterm Birth; Preterm Labor
Abstract
Inflammation inside the uterus is responsible for most of pregnancy complications, including preterm birth. Preterm birth is the leading cause of neonatal mortality and morbidity, and is associated with many diseases of the newborn which subject the infant to long-term disabilities. Of all inflammation mediators, interleukin-1 has been identified as a key player in uterine inflammation. However, currently available therapies that target interleukin-1 have failed to show expected efficacy at decreasing inflammation in gestational tissue. Our laboratory has recently developed a promising agent (termed 101.10) that targets interleukin-1 and decreases gestational inflammation. Preliminary data shows that it is also effective at improving newborn's health and decreasing long-term developmental problems. The proposed project aims to evaluate 101.10 efficacy, when administrated during gestation threatened by inflammation, to improve neonatal outcomes.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nadeau-Vallée, Mathieu
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~